Combined with our data showing TL1A is upstream of IL13, this indicates that targeting TL1A signaling offers an advantage over targeting IL13/IL4Rα or IL5 signaling in isolation to treat mucus secretion associated with asthma. This evidence concerns the gene IL4R and asthma.